Teva Pharmaceutical Industries Limited (TEVA): $6.18 million was the positive money flow into the stock on Thursday and the up/down ratio of ticks was also in favor of the bulls at 2.18. The value of trades done on upticks was $11.4 million, whereas, trades done on downticks were valued at $5.23 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $7.17 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $7.17 million. Teva Pharmaceutical Industries Limited (TEVA) fell $0 traded at $54.46, a change of 0% over the previous day. The stock is 7.01% for the week.
The stock has recorded a 20-day Moving Average of 7.77% and the 50-Day Moving Average is 6.18%. Shares have dropped -19.53% from its 1 Year high price. On Jul 28, 2015, the shares registered one year high at $72.31 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $51.77 and the 200 Day Moving Average price is recorded at $56.02.
Teva Pharmaceutical Industries Limited (NYSE:TEVA): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $54.82 and $54.42 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $55.07. The buying momentum continued till the end and the stock did not give up its gains. It closed at $54.98, notching a gain of 0.95% for the day. The total traded volume was 6,231,828 . The stock had closed at $54.46 on the previous day.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.